How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 77.5 | 77.5 | 78.1 | 76.2 | 76.2 | 76.2 | -1.2 |
| Healthcare | 20.1 | 20.1 | 18.8 | 19.9 | 19.9 | 19.9 | -0.2 |
| Chemicals | 0.8 | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | -0.2 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 12.42% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| APOLLOHOSP | Healthcare | 7.31% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| TORNTPHARM | Pharma | 4.75% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| JBCHEPHARM | Pharma | 4.73% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| AUROPHARMA | Pharma | 4.37% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| AJANTPHARM | Pharma | 3.99% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| MANKIND | Pharma | 3.89% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| LUPIN | Pharma | 3.73% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| ABBOTINDIA | Pharma | 3.65% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| FORTIS | Healthcare | 3.31% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| EMCURE | Pharma | 3.17% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| CIPLA | Pharma | 2.98% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| IPCALAB | Pharma | 2.43% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| SAILIFE | Healthcare | 2.26% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| ALKEM | Pharma | 2.03% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| DIVISLAB | Pharma | 1.82% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| LALPATHLAB | Healthcare | 1.38% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| PFIZER | Healthcare | 1.36% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| DRREDDY | Pharma | 1.36% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| BIOCON | Pharma | 1.23% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| GLAND | Pharma | 1.20% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| PPLPHARMA | Pharma | 1.16% | 6 | 1 | 5 | 4 | 6 | 0/2 | +14.5% |
| ANTHEM | Pharma | 1.13% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| VIJAYA | Pharma | 1.08% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| GLAXO | Healthcare | 0.75% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| MAXHEALTH | Healthcare | 0.71% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| JUBLPHARMA | Pharma | 0.66% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹186 (+86%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 122 vs Nifty 50 and 110 vs Nifty 500 — above 100, sustained outperformance.